Company: SXTPW
Filing Date: 2025-08-15
Form Type: PRE 14A
Source: 0001213900-25-077435
Chunk: 23

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-15
Form: PRE 14A
Chunk 23
---
 solicitations of proxies for election of directors in an election contest, or is otherwise
required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and Rule 14a-4(d) thereunder (including such person’s written consent to being named in the proxy statement as a nominee and to
serving as a director if elected); (B) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination
is made: (i) the name and address of such stockholder, as they appear on the Company’s books, and of such beneficial owner, (ii)
the class and number of shares of the Company that are owned beneficially and of record by such stockholder and such beneficial owner
and (iii) whether either such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy to holders of, in
the case of the proposal, at least the percentage of the Company’s voting shares required under applicable law to carry the proposal
or, in the case of a nomination or nominations, a sufficient number of holders of the Company’s voting shares to elect such nominee
or nominees.

Nominations and the solicitation notice should
be sent to the Nominating and Corporate Governance Committee, 60 Degrees Pharmaceuticals, Inc., 1025 Connecticut Avenue NW Suite 1000,
Washington, D.C. 20036.

As of the date of this Proxy Statement, we have
not received timely notice of any nomination by a stockholder.

Nominees for Director

The Nominating and Corporate Governance Committee
recommended to the Board and the Board nominated Mr. Dow, Mr. Allen, Ms. Xu, Mr. Toovey and Mr. Field to stand for election for the five
(5) Board seats. Each such individual has consented to serve if elected.

If elected, we expect that all of the aforementioned
nominees will serve as directors and hold office until the 2026 Annual Meeting of Stockholders and until their respective successors have
been elected and qualified or until their death, retirement or resignation.

Ethical Guidelines

60 Degrees Pharmaceuticals’ code of business
conduct and ethics (“Code”) was adopted to emphasize the Company’s commitment to the highest standards of business conduct.
The Code applies to our directors, officers and employees, including our principal executive officer, principal financial officer and
principal accounting officer or controller, or persons performing similar